

Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021

-- Conference Call Scheduled for Wednesday, November 3, 2021, at 8:30 a.m. ET --

NEWTON, Mass., Oct. 27, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Wednesday, November 3, 2021, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

SOURCE Karyopharm Therapeutics Inc.

For further information: Investors: Argot Partners, Jason Finkelstein/Matthew DeYoung, 212.600.1902 | karyopharm@argotpartners.com; Media: 720 Strategies, Andrew Lee, andrew.lee@720strategies.com

<https://investors.karyopharm.com/2021-10-27-Karyopharm-to-Report-Third-Quarter-2021-Financial-Results-on-November-3,-2021>